NGS-Based RNA-Sequencing

Global NGS-Based RNA-Sequencing Market to Reach US$13.2 Million by 2032

The global market for NGS-Based RNA-Sequencing estimated at US$3.9 Million in the year 2025, is expected to reach US$13.2 Million by 2032, growing at a CAGR of 19.0% over the analysis period 2025-2032. Sample Preparation Products Offering, one of the segments analyzed in the report, is expected to record a 21.1% CAGR and reach US$4.7 Million by the end of the analysis period. Growth in the RNA-Sequencing Platforms & Consumables Offering segment is estimated at 20.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Million While China is Forecast to Grow at 18.1% CAGR

The NGS-Based RNA-Sequencing market in the U.S. is estimated at US$1.1 Million in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.3 Million by the year 2032 trailing a CAGR of 18.1% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.9% and 16.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global NGS-Based RNA-Sequencing Market - Key Trends & Drivers Summarized

What Is NGS-Based RNA-Sequencing and Why Is It Transformative for Genomics?
Next-Generation Sequencing (NGS)-based RNA sequencing (RNA-Seq) is a high-throughput technique that allows scientists to analyze the entire transcriptome, identifying and quantifying RNA molecules in a sample at unprecedented resolution. This method enables researchers to explore gene expression, detect novel transcripts, and uncover alternative splicing events that are critical for understanding cellular functions. Unlike traditional sequencing technologies, NGS-based RNA-Seq provides a more comprehensive view of the transcriptome, helping researchers in fields like oncology, neurology, and immunology advance their understanding of diseases and develop new therapies.

The significance of NGS-based RNA sequencing lies in its ability to capture a dynamic picture of gene expression across various tissues, stages of development, and disease conditions. It is instrumental in biomarker discovery, drug development, and precision medicine by offering insights into how genes are regulated and expressed in different contexts. With RNA-Seq, researchers can investigate how environmental factors, genetic mutations, or therapeutic interventions affect gene activity, making it a transformative tool in both basic research and clinical applications.

How Is the NGS-Based RNA-Sequencing Market Evolving?
The NGS-based RNA sequencing market is evolving rapidly, driven by technological advancements and decreasing costs of sequencing. One of the key trends is the development of single-cell RNA sequencing (scRNA-Seq), which allows researchers to analyze gene expression at the single-cell level. This technique provides a more granular view of cellular heterogeneity, enabling the discovery of rare cell types, cell-state transitions, and immune responses within tissues. The integration of scRNA-Seq is becoming essential in areas like cancer research, where understanding tumor microenvironments and immune cell interactions can lead to better-targeted therapies.

Another significant trend is the increasing application of RNA-Seq in clinical diagnostics, particularly for cancer and rare genetic diseases. As precision medicine initiatives gain momentum, RNA-Seq is being used to identify disease-specific gene expression signatures that can guide treatment decisions. Additionally, the use of cloud-based platforms for RNA-Seq data analysis is growing, allowing researchers to process and interpret large datasets more efficiently. These advancements are making RNA-Seq more accessible to a broader range of researchers and clinicians, further expanding its adoption in both academic and commercial settings.

Which Industries Are Leading the Adoption of NGS-Based RNA-Sequencing?
NGS-based RNA sequencing is being widely adopted in both academic research and the pharmaceutical industry. In biomedical research, universities and research institutions are using RNA-Seq to study gene expression patterns in various diseases, including cancer, cardiovascular diseases, and neurological disorders. This technology is critical for understanding disease mechanisms and identifying potential therapeutic targets. Cancer research, in particular, is leading the adoption of RNA-Seq as it enables the discovery of oncogenes, tumor suppressor genes, and drug resistance mechanisms.

The pharmaceutical and biotechnology industries are also significant adopters of RNA-Seq, leveraging it for drug discovery and development. Pharmaceutical companies use RNA-Seq to identify biomarkers that can be targeted by new therapies, as well as to monitor patient responses to treatments in clinical trials. In clinical diagnostics, RNA-Seq is being integrated into precision medicine programs to develop personalized treatments based on a patient`s unique genetic and transcriptomic profile. The agricultural sector is also exploring RNA-Seq for crop improvement and the study of plant-pathogen interactions, highlighting its versatility across industries.

What Are the Key Growth Drivers in the NGS-Based RNA-Sequencing Market?
The growth in the NGS-based RNA sequencing market is driven by several factors, with the decreasing cost of sequencing being one of the most significant. As the cost per genome continues to drop, RNA-Seq is becoming more accessible to researchers and clinicians, leading to wider adoption across various fields. Another key driver is the increasing focus on precision medicine, which relies heavily on transcriptomic data to tailor treatments for individual patients. RNA-Seq provides the detailed gene expression information needed to develop personalized therapies, particularly in oncology and rare genetic disorders.

Technological advancements, such as single-cell RNA sequencing, are also propelling market growth by enabling more detailed and accurate analysis of gene expression. The expansion of RNA-Seq into clinical diagnostics is another important factor, as healthcare providers increasingly use RNA-based tests to diagnose diseases and monitor treatment responses. Additionally, the growing interest in understanding complex biological systems, such as the immune system and microbiome, is fueling demand for RNA-Seq as it offers deep insights into gene regulation and interaction networks.

SCOPE OF STUDY:

The report analyzes the NGS-Based RNA-Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product & Service (Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services, Data Analysis, Storage & Management); Technology (Sequencing by Synthesis (SBS), Single-Molecule Real-time (SMRT) Sequencing, Ion Semiconductor Sequencing, Nanopore Sequencing); End-Use (Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• Agilent Technologies, Inc.
• Eurofins Scientific
• F. Hoffmann-La Roche AG
• GATC Biotech AG
• Illumina, Inc.
• Macrogen, Inc.
• Oxford Nanopore Technologies Ltd.
• Pacific Biosciences of California, Inc.
• PerkinElmer, Inc.
• Qiagen NV
• Thermo Fisher Scientific, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more